<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B28E41AA-C3D0-4F6C-B6B8-E34E03131A75"><gtr:id>B28E41AA-C3D0-4F6C-B6B8-E34E03131A75</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>Ashcroft</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK002201%2F2"><gtr:id>B22A74F5-8E3D-4682-B47C-3C5918084574</gtr:id><gtr:title>Exploring the molecular interface between the HIF/hypoxia signalling pathway and mitochondria in cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K002201/2</gtr:grantReference><gtr:abstractText>Most organisms need oxygen to survive and generate energy efficiently. Mitochondria are essential subcellular compartments, present within all animal cells that consume oxygen and generate chemical energy. When cellular oxygen levels change, an &amp;quot;oxygen-sensor&amp;quot; called HIF-1alpha increases and switches on specific genes in the nucleus. We have discovered a human gene (CHCHD4) that encodes two mitochondrial proteins that interact with HIF-1alpha. Furthermore, we have also found that HIF-1alpha protein localizes with mitochondria in cells. We have previously shown that CHCHD4 proteins are essential for regulating the amount of HIF-1alpha protein available in the cell when cells experience low oxygen levels (hypoxia). This is important, because high levels of HIF-1alpha are associated with several human diseases including heart and kidney disease, stroke and cancer, where hypoxia is a key contributing factor to the pathology and severity of the disease. The role of HIF-1alpha protein localization with mitochondria and binding to CHCHD4 protein is not known. Thus, the proposed work will explore the molecular interface between HIF-1alpha and mitochondria with specific focus on the role of the HIF-alpha:CHCHD4 interaction in regulating mitochondrial function and metabolism in tumour cells. This work will help us identify novel mechanisms for how tumour cells adapt to their hypoxia microenvironment.</gtr:abstractText><gtr:technicalSummary>Hypoxia-inducible factors (HIF) are crucial, evolutionarily conserved components of the cellular oxygen sensing machinery that are activated when oxygen levels are low (hypoxia). Recent studies have highlighted an important role for mitochondria in relaying hypoxic signals to regulate HIF-1 in mammalian cells. For example, reactive oxygen species (ROS) produced in mitochondria, have been proposed to play a role in HIF-alpha stabilization during hypoxia. Pharmacological inhibitors of the respiratory chain, or genetic knockdown of cytochrome C or mitochondrial complex components have been shown to suppress hypoxia-induced ROS production and HIF-1alpha stabilization. Furthermore, HIF-1alpha can regulate mitochondrial function to optimize the efficiency of respiration in hypoxic cells by modulating the expression of cytochrome oxidase subunits. Thus, several studies connect mitochondria and components of the respiratory chain with HIF-1alpha induction and the hypoxic response, and vice versa. However, the molecular mechanisms underlying precisely how the HIF/oxygen sensing machinery interface with mitochondria remain unclear and this has been a long-standing question in the field. Using a bioinformatics approach, we have identified a new family of mitochondrial proteins (CHCHD4.1 and CHCHD4.2), that interact with HIF-1alpha under physiological conditions and are important regulators of HIF-1alpha-hypoxia signalling in vivo. CHCHD4.1 is identical to MIA40, which in yeast, functions to import proteins into the mitochondrial intermembrane space. The proposed work will investigate the role of the HIF-1alpha/hypoxia signalling pathway in directly regulating mitochondrial function and metabolism in tumour cells (in vitro and in vivo), with particular focus on exploring the relationship between HIF-1alpha and CHCHD4 proteins.</gtr:technicalSummary><gtr:potentialImpactText>The proposed work builds on our recent discoveries that show a novel molecular link between the HIF/hypoxia signalling pathway and mitochondria, that we have shown to have important clinical implications in the context of cancer (Briston et al, 2011; Yang et al, 2012). The knowledge gained from the proposed work will underpin a new avenue of research within the cell/cancer biology arena, and will be applicable to the disease setting in vitro and in vivo. The results obtained from our proposed work will be made public through publication in peer-reviewed open-access journals, and will be made publicly available by being deposited in public access databases when appropriate.
My laboratory has had a long-standing programme of work developing novel agents that target the HIF/hypoxia signalling pathway in cancer. As such, I am well-placed and well-connected to drive a translational effort that may result from the discoveries made from the proposed research. Indeed, the expert collaborators that are supporting this application are from multidisciplinary backgrounds. Collectively, they provide a breadth of expertise that will not only add value to the proposed work, but will also provide key input that could help underpin my broader translational vision for this project. A pathways to impact statement is included in this application.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>217331</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research Department of Cell and Developmental Biology (CDB)</gtr:department><gtr:description>Targeted knockout work</gtr:description><gtr:id>4BA09D45-A14D-4612-A7B1-04EEF2D5F44D</gtr:id><gtr:impact>Generation of targeted knock-out animals (on-going work)</gtr:impact><gtr:partnerContribution>Zebrafish expertise and targeted knock-out technology</gtr:partnerContribution><gtr:piContribution>Molecular biology expertise and know-how</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Takeda Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>106D116B-6EDC-4C06-8720-C3A4F523911E</gtr:id><gtr:impact>Presentation to identify areas for academic/industry alliance partnership (non-confidential), across the organization globally</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSK-Mitochondrial Workshop Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>77466A47-1957-4099-8D61-FF04522A4829</gtr:id><gtr:impact>Keynote presentation to GSK, to explore academic/industry partnerships</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Method of generation and characterisation of stable cell lines</gtr:description><gtr:id>BC4D2F78-E0B7-4D6C-A9E5-4534D8112B5F</gtr:id><gtr:impact>Increased speed data generation, and added value to other research</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stable cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DF5054D-9AB1-4183-ADEC-F05E3E4AF067"><gtr:id>3DF5054D-9AB1-4183-ADEC-F05E3E4AF067</gtr:id><gtr:title>CHCHD4 Regulates Intracellular Oxygenation and Perinuclear Distribution of Mitochondria</gtr:title><gtr:parentPublicationTitle>Frontiers in Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834b677bd2e0bb321587f8113cc676ce"><gtr:id>834b677bd2e0bb321587f8113cc676ce</gtr:id><gtr:otherNames>Ashcroft M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25894612-594A-40AE-96DD-E2AD89FBDD96"><gtr:id>25894612-594A-40AE-96DD-E2AD89FBDD96</gtr:id><gtr:title>CHCHD4 Regulates Intracellular Oxygenation and Perinuclear Distribution of Mitochondria</gtr:title><gtr:parentPublicationTitle>Frontiers in Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834b677bd2e0bb321587f8113cc676ce"><gtr:id>834b677bd2e0bb321587f8113cc676ce</gtr:id><gtr:otherNames>Ashcroft M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E90FB3C-95BA-4913-8466-79A980EEBF76"><gtr:id>1E90FB3C-95BA-4913-8466-79A980EEBF76</gtr:id><gtr:title>Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.</gtr:title><gtr:parentPublicationTitle>Journal of enzyme inhibition and medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6853e35f42d14041714dfa61ed69eab"><gtr:id>f6853e35f42d14041714dfa61ed69eab</gtr:id><gtr:otherNames>Pettersen EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-6366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CE3A076-6FDA-4F2B-8CAB-B4A1B95DC477"><gtr:id>3CE3A076-6FDA-4F2B-8CAB-B4A1B95DC477</gtr:id><gtr:title>Hypoxia Modulates Peptidyl Arginine Deiminase 4 Activity and Neutrophil Extracellular Trap Formation.</gtr:title><gtr:parentPublicationTitle>ARTHRITIS &amp; RHEUMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9babc5fb81f24f72f6d4cc7879d07fe6"><gtr:id>9babc5fb81f24f72f6d4cc7879d07fe6</gtr:id><gtr:otherNames>Khawaja Akif A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BDED14E-209C-4013-B55B-82011041CACB"><gtr:id>0BDED14E-209C-4013-B55B-82011041CACB</gtr:id><gtr:title>Mutations in mitochondrial DNA causing tubulointerstitial kidney disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e9a445c00d4a496e57ee743091335841"><gtr:id>e9a445c00d4a496e57ee743091335841</gtr:id><gtr:otherNames>Connor TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K002201/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>